Trials / Completed
CompletedNCT01358227
A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
A Phase I, Multi-center, Open-label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given Weekly in Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Proacta, Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PR104 | Dose escalation of PR104 to determine maximum tolerated dose for weekly administration |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2009-12-01
- Completion
- 2010-01-01
- First posted
- 2011-05-23
- Last updated
- 2011-05-24
Locations
2 sites across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT01358227. Inclusion in this directory is not an endorsement.